(IRWD)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
Ironwood Pharmaceuticals, Inc., biotexnologik kompaniya, Qo'shma Shtatlar va xalqaro miqyosda oshqozon-ichak (GI) va kam uchraydigan kasalliklarni davolash uchun terapiyalarni ishlab chiqish va tijoratlashtirishga qaratilgan. U LINZESS va CONSTELLA nomlari ostida qatga chiqish bilan bog'liq tirnash xususiyati beruvchi ichak sindromi yoki surunkali idiopatik qatga chiqishdan aziyat chekayotgan kattalar, shuningdek, funktsional qatga chiqishdan aziyat chekayotgan pediatrik bemorlarni davolash uchun guanililtsiklaza C turi (GC-C) agonisti bo'lgan linaklotidni sotadi. Kompaniya, shuningdek, ichak og'rig'i bilan bog'liq kasalliklarni, shu jumladan interstitsial sistit/sidik pufagi og'rig'i sindromi va endometriozni davolash uchun GC-C agonisti bo'lgan IW-3300; va parternal yordamga bog'liq bo'lgan ingichka ichak sindromi bemorlari, shuningdek, o'tkir graft-versus-host kasalligi uchun glyukagon-o'xshash peptid-2 ning sintetik peptidli uzoq muddatli analogi bo'lgan Apraglutidni ishlab chiqmoqda. U linaklotidni ishlab chiqish va tijoratlashtirish bo'yicha AbbVie Inc., AstraZeneca AB va Astellas Pharma Inc. bilan strategik hamkorlikka ega. Kompaniya ilgari Microbia, Inc. nomi bilan tanilgan va 2008 yil aprel oyida Ironwood Pharmaceuticals, Inc. nomini olgan. Ironwood Pharmaceuticals, Inc. 1998 yilda tashkil etilgan va shtab-kvartirasi Boston, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Michael Shetzline M.D., Ph.D. | Chief Medical Officer, Senior VP and Head of Research & Drug Development |
| Dr. Rosario Lobrutto M.B.A., M.S., Ph.D. | VP & Global Head of Technical Operations |
| Mr. Gregory Martini | Senior VP, CFO & Investor Relations |
| Mr. Jeff Ruberti | Chief Strategy Officer |
| Mr. John Minardo | Senior VP, Chief Legal Officer & Secretary |
| Mr. Ronald Silver | Senior VP, Corporate Controller & Principal Accounting Officer |
| Mr. Thomas A. McCourt | CEO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-11 | 8-K | tm268434d1_8k.htm |
| 2026-01-02 | 8-K | tm2534554d1_8k.htm |
| 2025-12-23 | 8-K | tm2534055d1_8k.htm |
| 2025-11-26 | 8-K | tm2532096d1_8k.htm |
| 2025-11-10 | 8-K | tm2530577d1_8k.htm |
| 2025-10-10 | 8-K | tm2528244d1_8k.htm |
| 2025-09-03 | 8-K | tm2525003d1_8k.htm |
| 2025-08-11 | 10-Q | irwd-20250630x10q.htm |
| 2025-08-07 | 8-K | tm2522671d1_8k.htm |
| 2025-07-10 | 8-K | tm2520217d1_8k.htm |
| Ms. Tammi Gaskins | Senior Vice President & Chief Commercial Officer. |